SAN DIEGO, Jan. 07, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce its Chief Executive Officer, Ms. Reggie Groves, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference at 9:30 a.m. US PST on Thursday, January 14, 2016. The conference is being held January 11th through 14th at The Westin St. Francis Hotel in San Francisco, California.
The presentation materials delivered at the conference will be available in the Investor Relations section of REVA’s website at www.revamedical.com on the day of the presentation. A copy of the presentation materials will also be lodged with the Australian Securities Exchange and filed with the U.S. Securities and Exchange Commission.
About REVA
REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the Fantom® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.
United States Investor & Media Enquiries: REVA Medical, Inc. Cheryl Liberatore Director, Communications +1 858-966-3045 Australia Investor Enquiries: Inteq Limited Kim Jacobs +61 2 9229 2700 Australia Media Enquiries: Buchan Consulting Rebecca Wilson +61 3 9866 4722 Annabel Murphy +61 2 9237 2800


Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 



